CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINST LoVo-N3 CELLS,A HIGHLY METASTATIC HUMAN COLON CANCER CELLLINE - Inhibitory effect of inflammation, rejection and metastasis -

1992 Fiscal Year Final Research Report Summary

• Project/Area Number: 03670587
• Research Category: Grant-in-Aid for General Scientific Research (C)
• Allocation Type: Single-year Grants
• Research Field: General surgery
• Research Institution: Okayama University
• Principal Investigator: KAMIKAWA Yasuaki Okayama University Medical School, First Department of Surgery Assistant Professor, 医学部附属病院, 講師 (00152851)
• Co-Investigator(Kenkyū-buntansha): NAOMOTO Yoshio Okayama University Medical School, First Department of Surgery Instructor, 医学部附属病院, 助手 (00237190) ; INOUE Fumiyuki Okayama University Medical School, First Department of Surgery Instructor, 医学部附属病院, 助手 (90223271) ; ORITA Kunzo Okayama University Medical School, First Department of Surgery Professor, 医学部, 教授 (20033053)
• Project Period (FY): 1991 – 1992
• Keywords: monoclonal antibody / metastasis / cancer

Research Abstract

Recently monoclonal antibodies (MAbs) capable of recognizing metastatic tumors have been reported. In order to obtain such monoclonal antibodies, BALB/c mice were immunized with highly metastatic tumor cell line. MAb II-28 and 243-5 obtained by immunization with metastatic LoVo-N3 inhibited the lung metastasis of RPMI4788 and the liver metastasis of LoVo-N3. The MAbs did not affect the cell growth in vitro. The metastasis inhibitory effect was supposed not due to cell damage mediated by ADCC and complement-dependent cytotoxicity. The 40kDa and 50kDa molecules recognized by MAb II-28 and 243-5 respectively are considered to play an important role in metastasisi of the cells.